Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 02 01; 30(2):325-331.